Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down28.000 -0.450 (-1.582%)

16/11/2021 15:33

Junshi Bio (01877) gets orphan-drug designation from FDA

[ET Net News Agency, 16 November 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said TopAlliance Biosciences, Inc., a subsidiary of the company, has received a
designation letter from the US Food and Drug Administration (the FDA), indicating that
toripalimab for the treatment of esophageal cancer has been granted the Orphan-drug
Designation by the FDA, which is the fourth Orphan-drug Designation obtained by
Toripalimab for the treatment of mucosal melanoma, nasopharyngeal carcinoma and soft
tissue sarcoma were previously granted the Orphan-drug Designation by the FDA. (RC)

Remark: Real time quote last updated: 30/03/2023 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.